Skip to main content
Sisram Medical Ltd logo

Sisram Medical Ltd — Investor Relations & Filings

Ticker · 1696 ISIN · IL0011418113 HKEX Manufacturing
Open in API
Filings indexed 1,569 across all filing types
Latest filing 2021-07-27 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 1696

About Sisram Medical Ltd

http://www.sisram-medical.com

Sisram Medical Ltd. is a global consumer wellness group specializing in medical aesthetics and minimally invasive solutions. Leveraging over two decades of expertise, the company is a leader in Energy-Based Devices (EBD), harnessing natural energy sources for both aesthetic and medical clinical indications. Sisram operates through a synergistic ecosystem of brands, providing medical-grade quality solutions to professional customers and consumers worldwide. Key segments include Alma, a provider of energy-based solutions for surgical and medical aesthetics markets; LMNT, a personal care brand for home use; Copulla, which offers end-to-end digital dentistry services; and a dedicated injectables portfolio. The company's extensive product range covers treatments such as hair removal, skin rejuvenation, body contouring, and dermal fillers.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and/or share buybacks for Sisram Medical Ltd. It includes detailed information about share issuance, including number of shares, issue price, and percentage changes. The document references compliance with listing rules of the Stock Exchange of Hong Kong (SEHK) and confirms authorization by the board of directors. The content is regulatory in nature, reporting a specific capital change event rather than providing a full financial report or earnings release. It is not a full annual or interim report, nor an earnings release or management discussion. The document is a formal regulatory disclosure about share capital changes, fitting the category of Share Issue/Capital Change (SHA). The document length (7903 characters) supports it being a substantive disclosure rather than a brief announcement or certification, so it is not RPA or RNS. Therefore, the best classification is SHA with high confidence.
2021-07-27 English
COMPLETION OF PLACING OF NEW SHARES UNDER THE ISSUANCE MANDATE
Capital/Financing Update Classification · 100% confidence The document is an announcement from Sisram Medical Ltd regarding the completion of a placing of new shares under an issuance mandate. It details the number of shares placed, the increase in total issued shares, and the shareholding structure post-placing. The document is relatively short (4378 characters) and focuses on the completion of a financing transaction involving new share issuance. There is no detailed financial report or analysis, but rather an update on capital structure changes due to the share placing. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes.
2021-07-27 English
PLACING OF NEW SHARES UNDER THE ISSUANCE MANDATE AND CONNECTED TRANSACTION
Capital/Financing Update Classification · 95% confidence The document is an announcement from Sisram Medical Ltd regarding the placing of new shares under an issuance mandate. It details the terms of the placing agreement, the number of shares to be issued, placing price, conditions, and effects on shareholding structure. The document is focused on a capital raising transaction involving new share issuance and connected transactions. It is not a full financial report, earnings release, or management discussion. It is not a proxy statement or voting result announcement. The document is lengthy (15,000 characters) and contains detailed information about the capital raising event. Therefore, it fits the category of Capital/Financing Update (CAP).
2021-07-20 English
DISCLOSEABLE AND CONNECTED TRANSACTIONS AND CONTINUING CONNECTED TRANSACTIONS RELATING TO THE SUBLICENSE AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement from Sisram Medical Ltd regarding a sublicense agreement entered into on July 14, 2021, involving connected transactions and continuing connected transactions. It details the terms of the sublicense, payments, and regulatory implications under the Hong Kong Stock Exchange Listing Rules. The document is an announcement of a transaction and related corporate actions, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but focuses on the transaction details and shareholder meeting arrangements. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a connected transaction and related corporate governance matters under listing rules, without being a full report or financial statement.
2021-07-14 English
DISCLOSEABLE AND CONNECTED TRANSACTION - UPDATE ON THE PROPOSED ACQUISITION
M&A Activity Classification · 95% confidence The document is an announcement from Sisram Medical Ltd regarding the completion of a proposed acquisition, specifically the acquisition of Shanghai Foshion Medical System Co., Ltd. It references previous announcements and a circular related to the acquisition. The content focuses on updating shareholders about the completion of the transaction, which is typical of M&A activity announcements. The document is short (1906 characters) and does not contain detailed financial statements or comprehensive analysis, so it is not an Annual Report or Interim Report. It is not a proxy solicitation, voting result, or regulatory filing unrelated to M&A. Therefore, the most appropriate classification is M&A Activity (TAR).
2021-07-13 English
ANNOUNCEMENT MADE PURSUANT TO RULES 13.51(2)(h) AND 13.51B(2) OF THE LISTING RULES
Board/Management Information Classification · 95% confidence The document is an announcement made pursuant to specific Listing Rules (13.51(2)(h) and 13.51B(2)) of the Hong Kong Stock Exchange. It discusses a public criticism of an executive director related to compliance with listing rules and the director's obligations, including required training. The document does not contain financial data, financial statements, or detailed management discussion. It is a regulatory announcement about a board member's conduct and compliance status rather than a full management or board report. This fits the category of Board/Management Information (MANG), which covers announcements of changes or issues related to the company's board or senior management. The document length is under 5,000 characters and is a standalone announcement, not a report publication or certification. Therefore, the appropriate classification is MANG with high confidence.
2021-07-13 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.